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Syndecan Captures, Protects, and Transmits
HIV to T Lymphocytes
surface HSPGs, such as midkine, inhibit HIV attachment
(Callebaut et al., 2001). Furthermore, the removal of cell
surface HS chains of proteoglycans using heparitinase
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Guido David,2 and Philippe A. Gallay1,* diminishes both HIV attachment to and infectivity of
CD4-positive HeLa cells as well as macrophages (Mondor1Department of Immunology
The Scripps Research Institute et al., 1998; Saphire et al., 1999, 2001). By forcing virus
attachment to the cell surface by centrifugation, we canLa Jolla, California 92037
2 Center for Human Genetics rescue HIV infectivity in cells devoid of cell surface HS
(Saphire et al., 2002). This result reinforces the notionUniversity of Leuven and
Flanders Interuniversity Institute that attachment represents a crucial and limiting step
in HIV entry. We recently showed that a specific classfor Biotechnology
B-3000 Leuven of HSPGs—the syndecans—when expressed in cis with
CD4 and chemokine receptors promote HIV attachmentBelgium
to target cells (Saphire et al., 2001). Specifically, we
found that macrophages express low CD4 levels but
abundant syndecan levels. Heparitinase which removesSummary
cell surface HS from syndecans decreases HIV attach-
ment to macrophages. This suggests that syndecans,This study demonstrates that syndecan functions as
an in trans HIV receptor. We show that syndecan, when by compensating for low CD4 levels in HIV attachment
modulate HIV replication. Although neither LFA-1 norexpressed in nonpermissive cells, becomes the major
mediator for HIV adsorption. This adsorption is medi- DC-SIGN nor syndecans alleviate the requirement for
CD4 and chemokine receptors for viral entry, these in cisated by the binding of gp120 to the heparan sulfate
chains of syndecan. Although syndecan does not sub- attachment receptors have an impact on HIV infection by
promoting viral adsorption to the surface of permissivestitute for HIV entry receptors, it enhances the in trans
infectivity of a broad range of primate lentiviruses in- cells.
In addition to its capacity to act as an in cis attachmentcluding primary viruses produced from PBMCs. Fur-
thermore, syndecan preserves virus infectivity for a receptor, DC-SIGN also functions as an in trans attach-
ment receptor for HIV. Specifically, DC-SIGN facilitatesweek, whereas unbound virus loses its infectivity in
less than a day. Moreover, we obtain evidence sug- HIV attachment to dendritic cells, whereas DC-SIGNR/
L-SIGN mediates HIV attachment to endothelial cellsgesting that the vast syndecan-rich endothelial lining
of the vasculature can provide a microenvironment (Soilleux et al., 2000; Geijtenbeek et al., 2000; Pohlmann
et al., 2001a; Bashirova et al., 2001). Similarly, the intro-which boosts HIV replication in T cells.
duction of DC-SIGN or DC-SIGNR/L-SIGN into human
cell lines boosts the capacity of these cells to attachIntroduction
HIV (Geijtenbeek et al., 2000; Pohlmann et al., 2001c;
Wu et al., 2002). Importantly, HIV attached to these non-Three main classes of HIV attachment receptors modu-
late the efficiency of entry mediated by CD4 and chemo- permissive cells via DC-SIGN represents a source of in
trans infectivity for T cells. The recognition that DC-kine receptors: LFA-1, DC-SIGN, and heparan sulfate
proteoglycans (HSPGs). Specifically, the presence of SIGN acts as in trans attachment receptor highlights the
importance of attachment receptors in HIV pathogene-LFA-1 on T cells promotes both HIV adsorption and
infectivity (Fortin et al., 1998). It is thought that interac- sis. It also raises the interesting possibility that cell sur-
face molecules other than DC-SIGN also possess thetions between ICAM-1, exposed at the surface of the
virus, and LFA-1, expressed on T cells, enhance HIV capacity to bind and to present HIV to permissive cells.
Given that syndecans, like DC-SIGN, efficiently attachattachment. Supporting this hypothesis, HIV replication
is decreased by agents which abrogate ICAM-1/LFA-1 HIV, they may represent a novel class of in trans HIV
receptors that have an impact on the tropism and dis-interactions (Bounou et al., 2002). Similarly, the expres-
sion of DC-SIGN together with CD4 and chemokine re- semination of the virus in vivo. In the present study, we
examined the potential of syndecans to act as in transceptors (in cis) enhances HIV entry. Indeed, the introduc-
tion of DC-SIGN in T cells expressing low CCR5 allows receptors for HIV.
entry and replication of R5 viruses in a CCR5-dependent
manner, a feature not exhibited by the parental cells Results
(Lee et al., 2001). Several lines of evidence suggest that
cell surface HSPGs act in an analogous manner to LFA-1 Syndecan Captures HIV onto the Surface
and DC-SIGN by promoting HIV attachment to target of Nonpermissive Cells
cells. Specifically, soluble heparin or heparan sulfate To investigate the potential of syndecans to act like DC-
(HS) (Schols et al., 1989; Patel et al., 1993; Mondor et SIGN as in trans attachment receptors, we compared
al., 1998) or the addition of factors known to bind to cell the capacity of syndecan and SIGN to attach HIV. To
explore this issue, we established a panel of cell lines
that express human syndecan-1, -2, -3, -4, DC-SIGN,*Correspondence: gallay@scripps.edu
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Figure 1. Syndecans Efficiently Capture HIV onto the Surface of Nonpermissive Cells via Their HS Chains
(A) Parental, syndecan-1, -2, -3, -4, DC-SIGN, and DC-SIGNR/L-SIGN-transfected Namalwa cells were examined for their cell surface expression
in heparan sulfates, syndecans, and SIGNs by FACS.
(B) Cells (0.25  106 cells) were exposed to PBMCs-derived R9 (X4) or R9BaL (R5) (1 ng of p24) for 2 hr at 37C, washed, and lysed, and p24
content was measured by ELISA. Results (duplicates) are expressed in percentage of p24 captured relative to the initial inoculum. This
experiment is representative of three independent experiments.
and DC-SIGNR/L-SIGN as described previously (Zhang interfere with the interpretation of the data. Namalwa
cells were stably transfected and analyzed for syndecanet al., 2001). The human B cell line Namalwa was chosen
as a parental cell line because these nonpermissive cells and DC-SIGN surface expression. Importantly, we found
that our panel of cell lines expresses similar levels of(CD4-negative) do not normally express any member of
the DC-SIGN or syndecan families (Zhang et al., 2001). syndecans and SIGNs (Figure 1A). We then tested the
capacity of these cell lines to attach HIV (R9 as X4 virusNote that traditional 293T cells were not used because
they naturally express significant HS levels which may and R9BaL as R5 virus) with that of parental Namalwa
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cells. Importantly, all viruses were produced from physi- Importantly, we found that the presence of syndecan-
positive nonpermissive cells enhance HIV infectivityological PBMCs instead of 293T cells. We found that
cells expressing DC-SIGN or DC-SIGNR/L-SIGN attach (2- to 5-fold) compared to the presence of syndecan-
negative parental cells or to cell-free virus alone (FigureHIV more efficiently than parental cells (Figure 1B). Fur-
thermore, we observed that DC-SIGN and DC-SIGNR/ 2C). Importantly, this enhancement of infectivity (5-fold;
93 versus 24 or 19 infected cells) is mostly observedL-SIGN attach R9 (X4 virus) more efficiently than R9BaL
(R5 virus) (Figure 1B). This is in accordance with a previ- using a low inoculum (0.2 ng of p24), suggesting that
virus binding to nonpermissive cells via syndecan, likeous study showing that DC-SIGN and DC-SIGNR/
L-SIGN more efficiently bind NL4.3 (X4 virus) than ADA via DC-SIGN, enhances in trans HIV infectivity at a low
MOI.(R5 virus) (Pohlmann et al., 2001a). Importantly, cells
expressing syndecan-1, -2, -3 or -4 also attach HIV more
efficiently than parental cells (Figure 1B). These data Primary HIV Isolates and a Majority of Primate
suggest that syndecans, like SIGNs, by promoting viral Lentiviruses Can Utilize Syndecans as In
adsorption, act as attachment receptors for HIV. trans Attachment Receptors
Previous studies showed that DC-SIGN and DC-SIGNR/
L-SIGN can bind multiple strains of HIV, HIV-2, and SIVSyndecans Capture and Efficiently Transmit HIV
and transmit these viruses to permissive cells (Pohl-to Permissive Cells
mann et al., 2001a, 2001b). Therefore, we examined theAfter demonstrating that syndecans efficiently capture
possibility that syndecans may also serve as in transHIV, we examined the possibility that syndecans act as
attachment receptors for primate lentiviruses other thanin trans HIV receptors by transmitting infectious parti-
HIV. Specifically, we tested the capacities of parental,cles to CD4 permissive cells. To address this issue,
syndecan-2-, and DC-SIGN-positive cells to attach andparental, syndecan-positive cells were pulsed with
transmit PBMC-derived HIV (R9, R9BaL, R7, 89.6, andPBMC-derived HIV (R9BaL) for 2 hr at 37C, washed,
JR-CSF), HIV-2 (Rod10), and SIV (mac239 and PBj 1.9)and cultured with permissive cells. The amounts of virus
as described above. We found that cells which expressinitially attached to the surface of the nonpermissive
DC-SIGN efficiently attach and transmit HIV-2 and SIVNamalwa cells were similar to those observed above
(Figures 3A and 3B) as described previously (Pohlmann(Figure 1B). We found that both DC-SIGN and DC-
et al., 2001a). Similarly, cells which express syndecan-2SIGNR/L-SIGN-positive cells efficiently transmit HIV to
efficiently attach and transfer HIV-2 and SIV to permis-CD4 HeLa cells, whereas parental cells do not (Figure
sive cells (Figures 3A and 3B). Furthermore, heparitinase2A). This confirms previous studies showing that DC-
treatment strongly diminished both attachment andSIGN and DC-SIGNR/L-SIGN act as an in trans HIV re-
transmission of HIV-2 and SIV (data not shown). To-ceptors (Geijtenbeek et al., 2000; Pohlmann et al.,
gether these results suggest that a majority of primate2001a). Most importantly, we found that each member
lentiviruses can bind to syndecans via their HS chainsof the syndecan family is capable of transmitting
and exploit them as in trans receptors to infect permis-attached HIV to permissive CD4 HeLa cells. Note that
sive cells. Note that the apparent discrepancy betweenheparitinase treatment abrogates the syndecan-medi-
HIV-2 and SIV binding and infection only arises from theated HIV capture (data not shown). Given that SIGNs
reduced capacity of HIV-2 and SIV to infect SMAGI cells.and syndecans attached R9BaL equally well (Figure 1B),
It is critical to note that our observation that primarythis suggests that the overall capacities of SIGNs and
viruses produced from their physiological in vivo tar-syndecans to transmit HIV are comparable. Note that
gets—PBMCs—efficiently bind to syndecans stronglywe obtained similar results using a range of viral inoculi
suggests that HIV-syndecan interactions occur in vivo.(from 0.1 to 10 ng of p24) (data not shown). Similarly,
we found that parental Namalwa cells that fail to attach
HIV (Figure 1B) do not transmit HIV to more physiological Heparan Sulfate-gp120 Interactions Mediate HIV
Capture by Syndecanstarget cells—PBMCs (Figure 2B). By contrast, synde-
can-2-positive cells as well as DC-SIGN-positive cells After demonstrating that syndecans on nonpermissive
cells possess the capacity to capture HIV produced fromefficiently transfer infectious particles to PBMCs (Fig-
ure 2B). Note that we obtained similar results for PBMCs to permissive cells, we examined which virus-
associated protein serves as a ligand for syndecans. Asyndecan-1, -3, and -4 (data not shown). It is important
to note that HIV fails to replicate in DC-SIGN- or synde- previous study suggested that gp120 is the major viral
ligand for cell surface HS. Specifically, Mondor et al.can-positive Namalwa cells in the absence of PBMCs
(data not shown). This indicates that syndecans, like showed that HIV originating from T cell lines efficiently
attaches to CD4-negative HeLa cells via HS. Importantly,DC-SIGN, cannot substitute for CD4 and chemokine re-
ceptors in HIV replication. Altogether these results dem- they found that antibodies directed against gp120 inhibit
the virus binding to HS on HeLa cells (Mondor et al.,onstrate that syndecans, by capturing and transmitting
HIV to permissive cells, may serve as in trans HIV re- 1998). Thus, to determine whether gp120 also functions
as a main ligand for HIV binding to syndecans, we fol-ceptors.
Given that HIV-DC-SIGN interactions enhance viral lowed a similar approach and tested the capacity of HIV
originating from PBMCs to bind to syndecans in thereplication (Geijtenbeek et al., 2000), we asked whether
HIV-syndecan interactions also promote in trans HIV presence of a panel of anti-gp120 antibodies. We found
that the CD4-induced epitope-specific 48d antibody asinfectivity. To explore this issue we measured HIV in-
fectivity in permissive CD4 HeLa cells in the presence well as the V3 loop 447-52D antibody efficiently inhibit
HIV capture by syndecans but do not influence HIV bind-or absence of nonpermissive syndecan-positive cells.
Immunity
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Figure 2. Syndecans Promote Transmission
of HIV to Permissive Cells
(A) Cells expressing syndecan and SIGN
members (0.25  106 cells) pretreated or not
with heparitinase were exposed to PBMCs-
derived R9BaL (R5) (1 ng p24) for 2 hr at 37C
and washed to remove unbound virus. Pulsed
cells (50,000) were added to P4CCR5 indica-
tor cells (80,000 cells). Infection was scored
by X-gal staining. Results (duplicates) are ex-
pressed in number of blue foci.
(B) Same as before except that R9BaL-pulsed
Namalwa cells were added to PBMCs (5 
106 cells). Viral replication was monitored by
p24 ELISA. Results (duplicates) are expressed
in g of p24/ml. This experiment is represen-
tative of three independent experiments.
(C) Decreasing amounts of R9BaL virus (5, 1,
and 0.2 ng of p24) together with parental or
syndecan-2-transfected Namalwa cells (50,000)
were added to P4CCR5 indicator cells (80,000
cells). Infection was scored by X-gal staining.
Results (duplicates) are expressed in number
of blue foci indicated at the end of the bar.
ing to DC-SIGN (Figure 4A). The anti-gp41 2F5 antibody with those of Mondor et al. (1998) suggest that synde-
cans capture HIV in a gp120-dependent manner.had no effect on HIV capture by syndecans, suggesting
that gp41 does not participate in HIV binding to synde- To further demonstrate that gp120 represents the
main ligand in HIV for HSPG binding, we pseudotypedcans. Interestingly, the mannose-dependent epitope-
specific 2G12 antibody and the CD4bs-specific IgG1b12 gp160-deleted virus (R9gp160) with the VSVG enve-
lope as described previously (Saphire et al., 1999). Vi-antibody enhanced HIV binding to syndecan-positive
cells but not to parental cells. This result suggests that ruses released from transfected 293T cells were used
to infect activated PBMCs. Twenty-four hours postinfec-the binding of these antibodies to gp120 promotes the
exposure of heparan binding sites within gp120. This tion, PBMCs were extensively washed and trypsinized
to remove the initial inoculum (VSVG-pseudotypedfinding suggests that the conformation of gp120 modu-
lates the capacity of the virus to bind to cell surface R9gp160) and cultured for several days. We observed
that gp160-deleted viruses were released from PBMCssyndecans. By demonstrating that anti-gp120 antibod-
ies block HIV binding to syndecans, our data together 1 week postinfection. Note that PBMCs infected with
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Figure 3. Syndecans Efficiently Capture and
Transmit a Majority of Primate Lentiviruses
(A) Parental, syndecan-2 and DC-SIGN-trans-
fected Namalwa cells were tested for their
capacities to capture PBMCs-derived R9
(NL4.3), R9BaL (BaL-pseudotyped R9), R7
(HXB-2), 89.6, JR-CSF, HIV-2 ROD 10, SIV
mac239, and SIV PBj 1.9 (1 ng of p24/p27) as
described in Figure 1. Results (duplicates) are
expressed in percentage of p24/p27 cap-
tured relative to the initial inoculum. This ex-
periment is representative of two indepen-
dent experiments.
(B) The capture assay was carried out as
above except that after washing the unbound
virus, cells (50,000) were added to indicator
cells (80,000). P4CCR5 cells were used for
R9, R9BaL, R7, 89.6, and JR-CSF, whereas
SMAGI were used for HIV-2, SIV mac239, and
SIV PBj 1.9. Infection was scored by X-gal
staining. Results (duplicates) are expressed
in number of blue foci. This experiment is
representative of two independent experi-
ments.
nonpseudotyped gp160-deleted viruses do not release from three conserved serines near the N terminus (ser-
ines at positions 37, 45, and 47) (Langford et al., 1998).any capsid in the milieu (data not shown). This indicates
that viruses produced from PBMCs infected with VSVG- Thus, we tested the capacity of a triple serine mutant
which lacks its three HS chains (called 3 synde-pseudotyped R9gp160 viruses truly represent de novo
released virions. After verifying that PBMC-produced can-1) to attach HIV. Wild-type and 3 syndecan-1 were
introduced into Namalwa cells and analyzed by FACSgp160-deleted viruses fail to infect CD4-positive HeLa
cells and do not express any viral envelope by Western for cell surface expression using antibodies which rec-
ognized either the HS chains or the core domain ofblot analysis using either anti-gp120 or anti-VSVG anti-
bodies (data not shown), we tested the capacity of these syndecan-1. We found that although both cell lines ex-
press similar levels of core proteins, the levels of HSviruses to bind to syndecans. In contrast to gp160-
deleted viruses produced from 293T cells, we found that greatly differ (Figure 4C). Indeed, cells which express
wild-type syndecan-1 exhibit high levels in HS, whereasgp160-deleted viruses produced from PBMCs fail to
bind to the HS chains of syndecans (Figure 4B). These cells expressing 3 syndecan-1 mutant have little HS.
We also found that the attachment capacity of cellsresults demonstrate that gp120 serves as the main li-
gand for syndecans when viruses are produced from expressing the HS-deficient mutant is reduced com-
pared to that of cells expressing wild-type syndecan-1physiological host PBMCs but not when viruses are pro-
duced from nonphysiological 293T. (Figure 4D). Altogether these results indicate that gp120-
HS interactions are absolutely required for HIV captureTo determine whether gp120 binds exclusively to the
HS chains of syndecans to permit HIV capture, synde- by cell surface syndecans.
can-positive cells were treated prior to HIV exposure
with heparitinase. We found that heparitinase treatment Syndecans Represent Major In trans Attachment
Receptors for HIV on Endothelial Cellsabrogates HIV attachment to syndecan-positive cells
but did not influence HIV attachment to DC-SIGN- Our observation that cells that express syndecans effi-
ciently capture and transmit HIV to permissive cells inpositive cells (data not shown). Previous studies demon-
strated that syndecans bear HS chains which originate trans suggests that cells which express syndecans in
Immunity
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Figure 4. Gp120-Heparan Sulfate Interactions Mediate HIV Capture by Syndecans
(A) Cells (0.25  106) were exposed to MN virus (X4) (1 ng of p24) originated from PBMCs for 2 hr at 37C in the presence of 10 g/ml of anti-
gp120 (48d, 447-52D, IgG1 B12, and 2G12) or gp41 (2F5) antibodies, washed, and lysed, and p24 content measured by ELISA. Results
(duplicates) are expressed in percentage of p24 captured relative to the initial inoculum. This experiment is representative of two independent
experiments.
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vivo may play a key role in HIV transmission, dissemina- HUVECs efficiently transfer HIV to PBMCs (Figure 5D).
Furthermore, the removal of cell surface HS stronglytion, and pathogenesis. One can imagine that sites con-
taining syndecan-expressing cells could represent ana- attenuated the capacity of HUVECs to transfer HIV to
PBMCs (Figure 5D). The residual capacity of HUVECstomical hot spots for high-efficiency HIV transmission.
Interestingly, syndecans are highly expressed on vascu- to transmit HIV after HS removal by heparinase suggests
that other binding factors such as adhesion moleculeslar endothelial cells (Mertens et al., 1992). Given that
lymphoid tissues represent the major sites for HIV repli- contribute to both viral capture and transmission. Note
that HIV fails to replicate in HUVECs in the absence ofcation in vivo (Pantaleo et al., 1994), we examined the
expression of syndecans in the vasculature of human PBMCs, suggesting that HUVECs alone do not support
viral growth. As a control, an amount of virus identicaladenoids. In accordance with previous works including
ours (Saphire et al., 2001), we found that T and B lympho- to that which was initially attached to HUVECs was
added to PBMCs without endothelial cells (Figure 5D).cytes express little HS (Figure 5A). In sharp contrast, we
found that the vasculature of the adenoids abundantly It is crucial to emphasize that the complete removal of
cell surface HS is required for efficient inhibition of HIV inexpresses HS (Figure 5A). Remarkably, HS staining de-
notes the outline of the vasculature of the adenoids. trans infection. Indeed, we observed that partial removal
only delays, but does not prevent HIV transfer to PBMCsInterestingly, we found that syndecan-3 perfectly delin-
eates the contour of some of the endothelial cell in high (data not shown). Interestingly, the replication of cell-
free virus in PBMCs was lower than the same amountendothelial venules (Figure 5A). The presence of synde-
cans on the endothelial cells lining afferent or efferent of virus initially attached to HUVECs (Figure 5D). This
enhancement of viral replication in PBMCs in the pres-venules raises the interesting possibility that syndecans,
by capturing and presenting HIV to passing permissive ence of endothelial cells correlates with the syndecan-
mediated in trans enhancement of infectivity observedT cells, could increase the efficiency of viral transmission
in these areas. above (Figure 2C). Altogether, these results demonstrate
that HIV captured onto the surface of endothelial cellsWe then examined the efficiency of syndecans on
endothelial cells to attach and transmit HIV to permissive via HS serves as a potent source of infectivity to T cells
in trans.cells. To address this issue, we used the human umbili-
cal vein endothelial cells (HUVECs) as archetypal endo-
thelial cells. We found that several members of the syn- HIV Captured by Nonpermissive Cells via Syndecans
Retains Infectivity Even after Long-Term Culturedecan family are expressed on HUVECs (Figure 5B).
Furthermore, we found that the combination of these A previous study showed that HIV bound to DC-SIGN
retains infectivity for more than 4 days (Geijtenbeek etsyndecans confers high HS levels on HUVECs (Figure
5B). Note that we were unable to detect DC-SIGNR/ al., 2000). Given that syndecans also attach and transfer
HIV, we compared the endurance of HIV attached toL-SIGN on these cells (Figure 5B). After verifying that
endothelial cells express syndecans, we tested the ca- syndecans with that of HIV attached to DC-SIGN. We
showed above that the capacity of syndecan-2 and DC-pacity of a monolayer of these cells to capture and
transmit HIV. Importantly, we found that the ability of SIGN to attach and transmit R9BaL (R5 virus) is very
similar (Figures 1 and 2). Thus, we compared the resis-HUVECs to attach and transmit HIV was comparable
with those of the syndecan-positive cells observed pre- tance of HIV attached to syndecan-2 with that of HIV
attached to DC-SIGN. Periodically, aliquots of the HIV-viously (Figure 2). Specifically, the levels of attachment
of R9 (X4 virus) and R9BaL (R5 virus) to HUVECs (Figure pulsed cells were added to permissive cells to measure
the infectivity of attached viruses. As a control, an5C) were similar to those of syndecan-2-positive Na-
malwa cells (Figure 2). Interestingly, we found that like amount of virus identical to that which was initially
attached to syndecan-2- and DC-SIGN-positive cellssyndecan-positive Namalwa cells, HUVECs attached X4
(R9) and R5 (R9BaL or JR-CSF) equivalently (Figure 5C). was incubated at 37C in medium without cells or with
parental Namalwa cells. As previously reported (Geijten-Most importantly, the removal of cell surface HS by
heparitinase decreased the capacity of HUVECs to at- beek et al., 2000), we found that cell-free virus or virus
incubated with parental Namalwa cells lost its infectivitytach HIV (Figure 5C).
After demonstrating that cell surface HS represent after 1 day (Figure 6A). This result strongly suggests
that HIV infectivity is extremely fragile in the extracellularmajor attachment sites for HIV on endothelial cells, we
tested the capacity of HUVECs to transmit attached milieu. In accordance with previous work, we found that
HIV attached to DC-SIGN retained its infectivity for 3particles to permissive cells. Importantly, we found that
(B) 293T cells were transfected with R9gp160 (30 g DNA) with or without VSVG envelope (5 g DNA). Nonpseudotyped R9gp160 and
VSVG-pseudotyped R9gp160 viruses released from 293T cells were used to infect PBMCs. Twenty-four hours postinfection, PBMCs were
extensively washed and trypsinized to remove the initial inoculum and cultured for several days. De novo R9gp160 viruses released from
PBMCs were quantified by measuring amounts of capsid in the supernatant of culture every 2 days by p24 ELISA. Syndecan-2-transfected
Namalwa cells treated or not with heparinase were tested for their capacities to capture R9 or R9gp160 (1 ng of p24) produced either from
293T or from PBMCs. Results (duplicates) are expressed in percentage of p24 captured relative to the initial inoculum. This experiment is
representative of two independent experiments.
(C) Parental, syndecan-1, and 3syndecan-1-transfected Namalwa cells were examined for cell surface expression in HS and syndecan-1 by
FACS analysis using antibodies directed against either heparan sulfate moieties or the core domain of syndecan-1.
(D) Parental, syndecan-1 and 3syndecan-1-transfected Namalwa cells were tested for their capacities to capture PBMC-derived R9BaL (R5)
(1 ng of p24) as described above. This experiment is representative of two independent experiments.
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Figure 6. HIV Attached to Syndecans Re-
tains Infectivity after Long-Term Culture
(A) Parental, syndecan-2, and DC-SIGN-
transfected Namalwa cells (0.25  106 cells)
were exposed to PBMC-derived R9BaL (1 ng
p24) for 2 hr at 37C, washed, and placed in
culture at 37C for several days. Every day,
aliquots of the R9BaL-pulsed Namalwa cells
were added to permissive P4CCR5 indicator
cells. As a control, an amount of virus identi-
cal to that which was initially attached to syn-
decan-2- and DC-SIGN-positive cells was in-
cubated at 37C in medium without cells or
with parental Namalwa cells (0.25 106 cells).
Infection was scored by X-gal staining. Re-
sults (triplicates) are expressed in number of
blue foci. This experiment is representative
of two independent experiments.
(B) HUVECs (0.25  106 cells) pretreated or
not with heparitinase were exposed to
PBMCs-derived R9BaL and processed as de-
scribed above. Each day, an endothelial
monolayer was detached and added to
P4CCR5 indicator cells.
days. Most importantly, we observed that HIV attached than 3 days, whereas unbound virus loses its infectivity
in less than a day. Importantly, the removal of HS byto syndecan-2 is infectious even after 5 days. Given that
the initial amounts of virus captured by syndecan-2 and heparitinase profoundly decreases the retention of HIV
infectivity (Figure 6B). Together these results suggestDC-SIGN were equivalent, these data suggest that syn-
decans not only capture and transmit HIV to permissive that syndecans on the surface of endothelial cells pro-
mote the endurance of the virus in the extracellularcells but also enhance the endurance of the virus. Simi-
larly, we asked whether heparan sulfated syndecans on milieu.
endothelial cells also preserve HIV infectivity. To ad-
dress this issue, HUVECs were treated or not with hepa- Discussion
ritinase, exposed to HIV for 2 hr at 37C, extensively
washed to remove viral inoculum, and incubated at 37C. Syndecan-Mediated HIV Capture onto
Nonpermissive CellsAs describe above, aliquots of the HIV-pulsed endothe-
lial cells were periodically added to permissive cells to We showed that syndecans exhibit a high capacity to
attach HIV to the cell surface of nonpermissive cells viameasure the infectivity of attached viruses. We found
that endothelial cells preserve virus infectivity for more their HS chains exclusively. Specifically, the removal of
Figure 5. Human Endothelial Cells Expressing Syndecans Capture and Transmit HIV to T Cells via HS
(A) (Left panel) Immunostained sections of paraformaldehyde-fixed and paraffin-embedded human adenoid tissue. Although HS (10E4) are
hardly detectable in the compartments that harbor B cells (CD20) and T cells (CD3), some lymphoid cells express syndecan-1 (BB4) and
syndecan-4 (8G3). (Right panel) Immunostained cryosections of human adenoid tissue, revealing the expression of HS (10E4), syndecan-3
(1C7), and the HECA 452 epitope, which is a carbohydrate primarily expressed on high endothelial venules, the preferred site of lymphocyte
extravasation in lymphoid tissues. HS abound in all blood vessels, whereas the follicles are essentially negative for HS. Note that HS,
syndecan-3, or HECA 452, all denote the outline of the cells in the high endothelial venules.
(B) HUVECs pretreated or not with heparitinase were examined for cell surface expression in HS, syndecans, and SIGNs by FACS.
(C) HUVECs (25,000 cells/ml) pretreated or not with heparitinase were exposed to PBMC-derived R9, R9BaL, or JR-CSF (1 ng p24) for 2 hr
at 37C, washed, and lysed, and p24 content was measured by ELISA. Results (duplicates) are expressed in percentage of p24 captured
relative to the initial inoculum.
(D) The capture assay was carried out as described above except that, after washing the unbound virus, PBMCs (3  106 cells) were added
on the top of adherent HIV-pulsed HUVECs. Viral replication was monitored by p24 ELISA. Results (duplicates) are expressed in g of p24/
ml. This experiment is representative of two independent experiments using PBMCs isolated from different donors.
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cell surface HS by heparitinase prevented HIV attach- cells. In one scenario, syndecans, by concentrating in-
fectious particles on the cell surface of nonpermissivement to nonpermissive cells via syndecans. Further-
more, we showed that a syndecan mutant which lacks cells, reduce virus diffusion and facilitate presentation
of HIV to permissive cells. Another scenario may be thatHS chains due to the introduction of mutations in the
glycosaminoglycan linkage motifs fails to capture HIV. syndecans create bridges between nonpermissive and
permissive cells. Indeed, previous studies showed thatA growing body of evidence suggests that the minimal
domains of HS chains required to bind distinct ligands syndecans possess the capacity to mediate aggregation
between cells. Specifically, syndecans-1 and -4 via theirdiffer from each other. For example, the interaction be-
tween antithrombin and HS depends on a very specific HS chains mediate intercellular adhesion following their
transfection into human lymphoid cells (Stanley et al.,structure of a pentasaccharide that contains a central
3-sulfated N-glucosamine residue (Bourin and Lindahl, 1995). Thus, it will be interesting to examine whether
syndecans, by creating contacts between nonpermis-1993). In a closer analogy to HIV, a study showed that
the herpes simplex virus type 1 requires specific sul- sive and permissive cells, increase the proximity be-
tween syndecan-attached HIV and CD4 and CCR5/fations in HS chains to infect host cells (Shukla et al.,
1999). Based on these premises, we can envision that CXCR4, and thus facilitate in trans infectivity.
HIV also recognizes specific binding motifs in HS chains
to attach to the cell surface via syndecans. Syndecan Preserves HIV Infectivity
We previously reported that HIV originating from non- We showed that HIV captured by nonpermissive cells
physiological 293T cells binds to syndecans in an enve- via syndecans retains infectivity for long time periods
lope-independent manner (Saphire et al., 1999). Specifi- in culture. Specifically, we found that HIV captured by
cally, we showed that envelope-deficient virus produced syndecans on nonpermissive cells remains a source of
from 293T cells attach to HS at levels similar to those of in trans infection even after 6 days of cell culture. Several
wild-type virus. Our observation that viruses produced mechanisms may explain the syndecan-mediated en-
from 293T cells differ from viruses derived from PBMCs durance of HIV. One mechanism may be analogous to
suggested that the cellular source of the virus is critical. that recently proposed for DC-SIGN-mediated endur-
For that reason, we reinvestigated the role of gp120 in ance of HIV. Specifically, Littman and colleagues ele-
HIV binding to syndecans using viruses originated from gantly demonstrated that DC-SIGN mediates rapid inter-
physiological PBMCs rather than from 293T cells. Spe- nalization of intact HIV into a low pH nonlysosomal
cifically, viruses produced from PBMCs were tested for compartment (Kwon et al., 2002). Importantly, internal-
their capacity to bind to syndecans in the presence of ized HIV remains able to infect permissive cells. It has
anti-gp120 antibodies. Importantly, we found that anti- been proposed that HIV binds to DC-SIGN to gain ac-
gp120 antibodies inhibit the syndecan-mediated cap- cess to an intracellular compartment that contributes to
ture of HIV demonstrating that gp120 is the main ligand augmentation or retention of viral infectivity. Thus, it
for syndecans when viruses are produced from physio- would be interesting to determine whether HIV bound
logical host PBMCs but not when viruses are produced to syndecans may also cycle in the cell to avoid long
from nonphysiological 293T. Most importantly, we contact with the hostile extracellular milieu. Importantly,
showed that PBMC-derived envelope-deficient viruses, syndecans undergo internalization and mediate a multi-
in contrast to 293T-derived envelope-deficient viruses, step endocytic pathway which includes ligand binding,
fail to attach to syndecans. It is likely that additional clustering, movement into rafts, and recruitment of actin
attachment factors provided by the membrane of 293T to bring the ligand into the cell (Fuki et al., 2000). Another
substitute for gp120 in HIV binding to syndecans. This mechanism that may explain the syndecan-enhanced
also indicates that the use of 293T cells for attachment endurance of HIV is that the long anionic linear HS chains
studies is not suitable. Altogether, these data indicate protect HIV from degradation. Indeed, previous studies
that HIV produced from its physiological targets— showed that in the presence of HS, FGF is fully protected
PBMCs—binds to syndecans in an envelope (gp120)- from tryptic digestion (Saksela et al., 1988). Treatment of
dependent manner. the HS with heparinase before addition of the protease
abolished the protection of FGF. Similarly, cytokines
capable to bind HS (i.e., IL-6 or IL-8) are protected fromHIV Transfer by Syndecans
protease degradation when bound to heparin, whereasWe showed that HIV captured by syndecans onto the
cytokines unable to bind heparin (i.e., IL-10) are rapidlycell surface of nonpermissive cells represents an impor-
degraded (Mummery and Rider, 2000). Thus, it will betant source of in trans infectivity for permissive cells.
interesting to determine whether HS chains of synde-Furthermore, we showed that, like HIV-DC-SIGN interac-
cans protect captured HIV from proteolytic attack andtions, HIV-syndecan interactions enhance HIV infectivity
preserve its infectivity.in trans. Specifically, we found that the presence of
syndecan-positive nonpermissive cells enhances in-
fectivity (2- to 5-fold) compared to the presence of syn- Significance of Syndecans for HIV Pathogenesis
We presented several lines of evidence linking the endo-decan-negative nonpermissive cells or to cell-free virus.
Importantly, this syndecan-mediated enhancement of thelium to HIV pathogenesis by demonstrating that syn-
decans serve as major in trans HIV receptors. Specifi-infectivity is mostly observed at a low MOI. However,
the precise molecular mechanisms controlling the trans- cally, we showed that endothelial cells both in vivo and
in vitro richly express heparan sulfated syndecans. Wefer of HIV bound to syndecans on nonpermissive cells to
CD4/CXCR4/CCR5 entry receptors on permissive cells also showed that primary human endothelial cells pos-
sess a remarkable capacity to attach and transfer HIVremain to be elucidated. Several scenarios may explain
how syndecans facilitate HIV transmission to permissive to permissive cells. We found that the removal of cell
In trans HIV Transmission by Syndecan
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Figure 7. Model for Syndecan-Mediated HIV In trans Transmission
or primary viruses JR-CSF (R5 virus) and 89.6 (R5X4 virus) weresurface HS reduced HIV capture and in trans transmis-
produced from PHA/IL-2 activated PBMCs and purified as describedsion, ultimately delaying viral replication kinetics. These
previously (Saphire et al., 1999). Viral load was standardized by p24results suggest that HSPGs expressed on endothelial
antigen by ELISA (NEN-Dupont) or by p27 antigen by p27 ELISA
cells serve as major in trans attachment receptors for (ZeptoMetrix). Infections were performed using the P4CCR5 (for
HIV. To place this finding in its proper context, the total HIV) or SMAGI (for HIV-2 and SIV) indicator cell lines. P4CCR5 and
SMAGI cells express CD4, which renders them susceptible to infec-surface area of the endothelial lining of the vasculature
tion, and contain an integrated Escherichia coli lacZ gene driven byis estimated to be at least 600 square meters; this sug-
the HIV or HIV-2/SIV LTR. Upon infection, Tat production from thegests that the endothelium may represent an abundant,
integrated provirus leads to activation of the lacZ reporter, resultingif not the major, in trans viral reservoir in the body (Figure
in synthesis of -galactosidase in these cells. Infected cells are
7, proposed model). Furthermore, we not only show that, identified by staining with X-gal 48 hr postinoculation, allowing
once bound to syndecans on the endothelium, HIV can quantitation after a single round of infection.
either be retained in an infectious state for several days
or can be transmitted to circulating T cells, but we also
Cells and Antibodiesshow that endothelial syndecans actually boost HIV rep-
Human umbilical vein endothelial cells (ATCC number CRL-1730)
lication in T cells in trans. We can envision that this mode were cultured accordingly to ATCC’s recommendations. PBMCs
of transmission provided by syndecans richly expressed were isolated by Ficoll-Hypaque gradient centrifugation and stimu-
on the capillaries, where the velocity of the blood flow lated with PHA and IL-2 as described previously (Saphire et al.,
2001). Parental Namalwa were transfected by electroporation withis tranquil, may represent hot spots for HIV replication.
human syndecan-1, -2, -3, -4, DC-SIGN, and DC-SIGNR/L-SIGNThus, our findings highlight the importance of the HIV-
cloned in pcDNA3-neo as described previously (Zhang et al., 2001).syndecan interaction because they demonstrate that
Transfectants were maintained by selection with 500 g/ml of G418
syndecan-rich endothelial cells can provide a microenvi- for several weeks. Stability of syndecan and SIGN expressions were
ronment that amplifies HIV replication in T cells and may carefully examined at the time of capture or infection assays by
thus have a profound impact on HIV pathogenesis. FACS analysis. Cell surface expression of HS was examined by anti-
HS antibody (clone 10E4) (Seikagaku). Cell surface removal of HS
by using heparitinase (10 U) (Sigma) was performed as describedExperimental Procedures
previously (Saphire et al., 1999). The expression of human synde-
can-1, -2, -3, and -4 was analyzed using antibodies directed againstViruses and Infections
Laboratory-adapted viruses R9 (NL4.3 derivative) (X4 virus), R9BaL the core ectodomain of syndecan-1 (clone ID4) (Biogenesis),
syndecan-2 (clone F58-10H4), syndecan-3 (clone F58-1C7), and(BaL-pseudotyped R9) (R5 virus), R7 (HXB-2 derivative) (X4 virus),
MN (X4 virus), HIV-2 ROD10, SIV mac239 and SIV PBj 1.9 viruses, syndecan-4 (clone F94-8G3). Wild-type and 3 (S37A, S45A, and
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S47A) syndecan-1 (Langford et al., 1998) were detected using an Knolle, P.A., et al. (2001). A dendritic cell-specific intercellular adhe-
sion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein isanti-murine syndecan-1 antibody (clone 281-2) (BD Pharmingen).
Cell surface expressions of SIGNs were examined using an anti- highly expressed on human liver sinusoidal endothelial cells and
promotes HIV infection. J. Exp. Med. 193, 671–678.DC-SIGN antibody (clone DC28) (AIDS Research and Reference Pro-
gram). 48d, 447-52D, IgG1 b12, and 2G12 anti-gp120 antibodies as Bounou, S., Leclerc, J.E., and Tremblay, M.J. (2002). Presence of
well as the 2F5 anti-gp41 antibody were obtained through the AIDS host ICAM-1 in laboratory and clinical strains of humanimmunodefi-
Research and Reference Program. ciency virus type 1 increases virus infectivity and CD4()-T-cell
depletion in human lymphoid tissue, a major site of replication in
Immunohistochemistry vivo. J. Virol. 76, 1004–1014.
Cryosections of human adenoid tissue were fixed in acetone and Bourin, M.C., and Lindahl, U. (1993). Glycosaminoglycans and the
incubated with primary antibodies, e.g., mouse monoclonal anti-HS regulation of blood coagulation. Biochem. J. 289, 313–330.
(10E4; 20 g/ml), mouse monoclonal anti-human syndecan-3 (1C7;
Callebaut, C., Nisole, S., Briand, J.P., Krust, B., and Hovanessian,10 g/ml), and rat monoclonal anti-human cutaneous lymphocyte
A.G. (2001). Inhibition of HIV infection by the cytokine midkine. Virol-antigen (HECA-452; dilution 1/50), followed by 1 hr incubation with
ogy 281, 248–264.biotinylated goat anti-mouse or rabbit anti-rat immunoglobulin (dilu-
Fortin, J.F., Cantin, R., and Tremblay, M.J. (1998). T cells expressingtion 1/300), and by incubation with the Vectastain ABC elite kit
activated LFA-1 are more susceptible to infection with human immu-(Vector Lab, Burlingame, CA). Diaminobenzidinetetrahydrochloride
nodeficiency virus type 1 particles bearing host-encoded ICAM-1.(DAB, Sigma) was used as substrate. Alternatively, human adenoid
J. Virol. 72, 2105–2112.tissue was fixed with paraformaldehyde and embedded in paraffin.
Deparaffinated sections were subjected to microwave treatment Fuki, I.V., Meyer, M.E., and Williams, K.J. (2000). Transmembrane
and blocked with hydrogen peroxide (0.3%) in methanol and with and cytoplasmic domains of syndecan mediate a multi-step endo-
PBS-BSA-goat serum. Sections were incubated overnight with ei- cytic pathway involving detergent-insoluble membrane rafts. Bio-
ther mouse monoclonal anti-HS (10E4; 20g/ml), anti-human synde- chem. J. 351, 607–612.
can-1 (BB4; Serotec, Oxford, England; 10g/ml), anti-human synde-
Geijtenbeek, T.B., Kwon, D.S., Torensma, R., van Vliet, S.J., van
can-4 (8G3; 10 g/ml), or anti-human CD20 (B cell marker; Dako;
Duijnhoven, G.C., Middel, J., Cornelissen, I.L., Nottet, H.S., Kewal-
dilution 1/50), or with rabbit polyclonal anti-human CD3 (T cell
Ramani, V.N., Littman, D.R., et al. (2000). DC-SIGN, a dendritic cell-
marker; Dako; dilution 1/50). Further incubations were executed as
specific HIV-binding protein that enhances trans-infection of T cells.
above, but VIP (Vector Lab) was used as a peroxidase substrate,
Cell 100, 587–597.
and the sections were counterstained with methylgreen (Vector Lab).
Kwon, D.S., Gregorio, G., Bitton, N., Hendrickson, W.A., and Littman,
D.R. (2002). DC-SIGN-mediated internalization of HIV is required forCapture and Transmission Assay
trans enhancement of T cell infection. Immunity 16, 135–144.Virus capture assay was performed as described previously (Pohl-
Langford, J.K., Stanley, M.J., Cao, D., and Sanderson, R.D. (1998).mann et al., 2001a). In brief, Namalwa cells (0.25  106 cells/500 l
Multiple heparan sulfate chains are required for optimal syndecan-1complete RPMI) were exposed to virus (1 ng of p24) for 2 hr at 37C,
function. J. Biol. Chem. 273, 29965–29971.washed three times with 3 ml of PBS, lysed in Triton X-100, and
p24/p27 content was measured by ELISA. Cells were treated or not Lee, B., Leslie, G., Soilleux, E., O’Doherty, U., Baik, S., Levroney,
with heparitinase (10 U/ml) (Sigma) for 1 hr and washed prior to viral E., Flummerfelt, K., Swiggard, W., Coleman, N., Malim, M., and
exposure. For the transmission assay, pulsed cells were washed Doms, R.W. (2001). cis expression of DC-SIGN allows for more effi-
three times with 3 ml of PBS and titrated on permissive cells. To cient entry of human and simian immunodeficiency viruses via CD4
quantify the transfer, we used two types of permissive cells: either and a coreceptor. J. Virol. 75, 12028–12038.
CD4 HeLa indicator cells (P4CCR5 for HIV or SMAGI for HIV-2 and
Mertens, G., Cassiman, J.J., Van den Berghe, H., Vermylen, J., and
SIV) permitting the analysis of a single round of infection or PHA/
David, G. (1992). Cell surface heparan sulfate proteoglycans from
IL-2-stimulated PBMCs permitting the analysis of multiple round of
human vascular endothelial cells. Core protein characterization and
infection.
antithrombin III binding properties. J. Biol. Chem. 267, 20435–20443.
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